Related Experiment Videos
The comparative bioavailability of Lanoxin tablets and Lanoxicaps with and without sorbitol
European Journal of Clinical Pharmacology
|December 18, 1978
Summary
Lanoxicaps demonstrated enhanced digoxin absorption compared to traditional tablets, with urinary excretion averaging 60% versus 50%. This improved bioavailability was consistent across various Lanoxicaps formulations and independent of sorbitol content.
Area of Science:
- Pharmacokinetics
- Drug Absorption
- Bioavailability Studies
Background:
- Digoxin is a critical medication for heart failure and arrhythmias.
- Understanding digoxin formulations' bioavailability is essential for therapeutic efficacy.
- Lanoxicaps represent an alternative oral delivery system for digoxin.
Purpose of the Study:
- To compare the pharmacokinetic profiles of different digoxin formulations.
- To assess the impact of formulation type (capsule vs. tablet) on digoxin absorption.
- To investigate the role of sorbitol in Lanoxicaps bioavailability.
Main Methods:
- Eight healthy volunteers participated in the study.
- Single oral doses of various digoxin formulations were administered.
- Cumulative urinary digoxin excretion was measured over 8 days.
Main Results:
- Lanoxicaps showed significantly higher mean urinary digoxin excretion (60%) compared to tablet formulations (50%).
- No significant differences in excretion were observed among different Lanoxicaps formulations.
- Digoxin tablets (0.2 mg) exhibited lower cumulative urinary excretion than all other treatments.
- Lanoxin tablets (0.25 mg) showed lower excretion than 0.1 mg Lanoxicaps without sorbitol.
Conclusions:
- Lanoxicaps provide enhanced digoxin absorption compared to traditional tablets.
- The enhanced absorption is not influenced by the sorbitol content in the capsule shell.
- Formulation significantly impacts digoxin bioavailability, with Lanoxicaps offering a more efficient delivery.